Literature DB >> 2203898

Hemodynamic effects of adenosine agonists in the conscious spontaneously hypertensive rat.

R L Webb1, R B McNeal, B W Barclay, G D Yasay.   

Abstract

The present studies examined the underlying hemodynamic mechanisms contributing to the reduction in blood pressure observed in conscious spontaneously hypertensive rats after systemic administration of adenosine agonists. The effects produced by i.v. and i.a. injections of 2-phenylaminoadenosine [CV-1808, adenosine (A2) selective agonist], 5'-N-ethylcarboxamide adenosine (NECA, nonselective agonist), 2-chloroadenosine (2-CADO, A1 selective agonist) and cyclopentyladenosine (CPA, A1 selective agonist) were evaluated and compared to those of hydralazine. All agents produced hypotensive effects after bolus i.v. injection. Although CPA, NECA and 2-CADO elicited dose-dependent bradycardia, CV-1808 and hydralazine increased heart rate. These effects, with the exception of the hydralazine-evoked responses, were attenuated by prior treatment with 8-(p-sulfophenyl)theophylline (2 mg/kg/min), whereas both CV-1808 and hydralazine produced regional vasodilation, significant increases in blood flow occurred only after CV-1808 (3-30 micrograms/kg). The regional hemodynamic responses to NECA were more complex; low doses (0.1-1 microgram/kg) produced consistent reductions in regional vascular resistance, whereas at the highest dose renal vasoconstriction occurred. Although regional vasodilation occurred after 2-CADO, mesenteric vasoconstriction was observed subsequent to CPA administration. Whereas a significant increase in renin release was evident in animals treated with CV-1808 and hydralazine, no change occurred in response to the NECA-, 2-CADO- or CPA-induced hypotension. We conclude that the predominant hemodynamic response after selective activation of A2 receptors is one of regional vasodilation and hypotension leading to a reflex increase in heart rate and renin release.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2203898

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  12 in total

1.  Role of central and peripheral adenosine receptors in the cardiovascular responses to intraperitoneal injections of adenosine A1 and A2A subtype receptor agonists.

Authors:  Charles W Schindler; Marzena Karcz-Kubicha; Eric B Thorndike; Christa E Müller; Srihari R Tella; Sergi Ferré; Steven R Goldberg
Journal:  Br J Pharmacol       Date:  2005-03       Impact factor: 8.739

2.  Adenosine-mediated hypotension in in vivo guinea-pig: receptors involved and role of NO.

Authors:  P Nieri; E Martinotti; V Calderone; M C Breschi
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

3.  Partial agonism of theophylline-7-riboside on adenosine receptors.

Authors:  A P IJzerman; E M van der Wenden; J K von Frijtag Drabbe Künzel; R A Mathôt; M Danhof; P A Borea; K Varani
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-12       Impact factor: 3.000

4.  Deoxyribose analogues of N6-cyclopentyladenosine (CPA): partial agonists at the adenosine A1 receptor in vivo.

Authors:  R A Mathôt; E M Van der Wenden; W Soudijn; A P IJzerman; M Danhof
Journal:  Br J Pharmacol       Date:  1995-10       Impact factor: 8.739

5.  The cardiovascular effects of selective adenosine A1 and A2 receptor agonists in the pithed rat: no role for glibenclamide-sensitive potassium channels.

Authors:  J R Fozard; A M Carruthers
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-02       Impact factor: 3.000

6.  Modelling of the pharmacodynamic interaction of an A1 adenosine receptor agonist and antagonist in vivo: N6-cyclopentyladenosine and 8-cyclopentyltheophylline.

Authors:  S Appel; R A Mathôt; M W Langemeijer; A P IJzerman; M Danhof
Journal:  Br J Pharmacol       Date:  1995-08       Impact factor: 8.739

7.  A link between adenosine, ATP-sensitive K+ channels, potassium and muscle vasodilatation in the rat in systemic hypoxia.

Authors:  J M Marshall; T Thomas; L Turner
Journal:  J Physiol       Date:  1993-12       Impact factor: 5.182

8.  Pharmacokinetic-haemodynamic relationships of 2-chloroadenosine at adenosine A1 and A2a receptors in vivo.

Authors:  R A Mathoôt; W Soudijn; D D Breimer; A P Ijzerman; M Danhof
Journal:  Br J Pharmacol       Date:  1996-05       Impact factor: 8.739

9.  Pharmacokinetic modelling of the haemodynamic effects of the A2a adenosine receptor agonist CGS 21680C in conscious normotensive rats.

Authors:  R A Mathôt; A Cleton; W Soudijn; A P IJzerman; M Danhof
Journal:  Br J Pharmacol       Date:  1995-02       Impact factor: 8.739

10.  Regional haemodynamic responses to adenosine receptor activation vary across time following lipopolysaccharide treatment in conscious rats.

Authors:  L Jolly; J E March; P A Kemp; T Bennett; S M Gardiner
Journal:  Br J Pharmacol       Date:  2008-05-26       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.